Verification of the interaction between peptide T and CD4 using surface plasmon resonance

Tracie E. Ramsdale, Peter R. Andrews, Edouard C. Nice

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)


Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gp120-induced neuronal toxicity. However, a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding can be specifically inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented.

Original languageEnglish
Pages (from-to)217-222
Number of pages6
JournalFEBS Letters
Issue number3
Publication statusPublished - 1 Nov 1993
Externally publishedYes


  • AIDS-associated dementia
  • Biosensor
  • Kinetics
  • Peptide T
  • Surface plasmon resonance

Cite this